<!DOCTYPE html><html><head><title>Advanced chronic kidney disease (CKD): percent of patients with antihypertensive therapy intensified.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Advanced chronic kidney disease (CKD): percent of patients with antihypertensive therapy intensified.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Renal Physicians Association. Appropriate patient preparation for renal replacement therapy. Rockville (MD): Renal Physicians Association; 2002 Oct 1. 78 p.&nbsp;(Clinical Practice Guideline; no. 3).</td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Process<div class="content_special_handling"><p>The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the <a href="/selecting-and-using/validity.aspx">Measure Validity</a> page.<p/></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure assesses the percent of patients with antihypertensive therapy intensified among patients with advanced chronic kidney disease (CKD) with blood pressure greater than 130/80 mmHg and on antihypertensive medications.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patients with advanced chronic kidney disease (CKD) are situated at a crossroads between patients with less severe chronic kidney disease, where strict blood pressure control is a well established mainstay of therapy, and patients on dialysis, where blood pressure goals are not well understood. In the absence of strong scientific data to define therapeutic targets, blood pressure goals in dialysis patients remain extrapolated from the general population. Because of significantly increased cardiovascular risk in patients with both advanced CKD and diabetes, management of patients with both conditions deserves special attention.</p>

<p>Based on data from patients with advanced CKD as well as extrapolation from those with less severe CKD, lowering blood pressure is an important goal in the advanced CKD population.</p>

<p>Elevated blood pressure is clearly an important risk factor for rapid progression of kidney disease and for cardiac hypertrophy.</p>

<p>Lifestyle modifications improve blood pressure control in the general population and this evidence was deemed by the measure developer to be applicable to patients with advanced CKD.</p>

<p>Studies that specifically examine the use of pharmacological antihypertensive therapy in patients with glomerular filtration rate (GFR) less than or equal to 30 mL/min/1.73 m<sup>2</sup> show that blood pressure can be lowered in this population. In a small number of studies, reduction in blood pressure with antihypertensive medication has been shown to improve measures of renal disease progression and cardiac hypertrophy in patients with advanced CKD.</p>

<p>This recommendation is also based on extrapolation from patients with less severe CKD (GFR greater than 30 mL/min/1.73 m<sup>2</sup>). Reduction in blood pressure with antihypertensive medication clearly improves measures of kidney function, slows the progression to end-stage renal disease (ESRD), and improves clinical outcomes such as clinical cardiovascular events and mortality in these individuals.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Clinical Component
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Advanced chronic kidney disease; hypertension; antihypertensive therapy</p> </div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of adult patients with advanced chronic kidney disease (CKD), not currently receiving renal replacement therapy, with blood pressure greater than 130/80 mmHg, and on antihypertensive medications</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients from the denominator with antihypertensive therapy intensified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Evidence Supporting the Criterion of Quality
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence
</div>
<div class='FieldValue'>
A formal consensus procedure involving experts in relevant clinical, methodological, and organizational sciences
</div>
<div class='FieldValue'>
A systematic review of the clinical literature
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting Need for the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Need for the Measure
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Pilot testing
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
Internal quality improvement
</div>

</div>

</div>
<div class='section'>
<h2>Application of Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Care Setting
</h3>
<div class='FieldValue'>
Ambulatory Care
</div>
<div class='FieldValue'>
Physician Group Practices/Clinics
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Professionals Responsible for Health Care
</h3>
<div class='FieldValue'>
Physicians
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Lowest Level of Health Care Delivery Addressed
</h3>
<div class='FieldValue'>
Individual Clinicians
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Age greater than or equal to 18 years</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>
<div class='field field_text'>
<h3>
Stratification by Vulnerable Populations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Characteristics of the Primary Clinical Component
</h2>
<div class='field field_text'>
<h3>
Incidence/Prevalence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Association with Vulnerable Populations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Burden of Illness
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Elevated blood pressure is clearly an important risk factor for rapid progression of kidney disease and for cardiac hypertrophy.</p>
</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Burden of Illness
</h3>
<div class='FieldValue'>
<table><tr><td>Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996 May;49(5):1379-85. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8731103" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Ren Replace Ther. 1997 Jul;4(3):234-48. [160 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9239428" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant. 1990;5(1):39-44. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2109283" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Shiigai T, Hattori K, Iwamoto H, Owada A. Long-term enalapril therapy in patients with chronic renal failure on a low-protein diet. A prospective randomized comparison with metoprolol. Nephron. 1998;79(2):148-53. [45 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9647493" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Utilization
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Costs
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Case Finding
</h3>
<div class='FieldValue'>
Users of care only
</div>

</div>
<div class='field field_text'>
<h3>
Description of Case Finding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Adult patients 18 years and older with advanced chronic kidney disease (CKD), blood pressure greater than 130/80 mmHg, and on antihypertensive medications</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br>
Adult patients age 18 years and older with chronic kidney disease stage 4 or 5 (glomerular filtration rate [GFR] less than or equal to 30 mL/min/1.73 m<sup>2</sup>), not currently receiving renal replacement therapy, with blood pressure greater than 130/80 mmHg, and on antihypertensive medications</p>

<p><strong>Exclusions</strong><br>
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Relationship of Denominator to Numerator
</h3>
<div class='FieldValue'>
All cases in the denominator are equally eligible to appear in the numerator
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Therapeutic Intervention
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
Time window precedes index event 
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br>
The number of patients from the denominator with antihypertensive therapy intensified<sup>*</sup></p>

<p><sup>*</sup>Intensification of antihypertensive therapy: increasing medication dosage and/or adding medications</p>

<p><strong>Exclusions</strong><br>
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Measure Results Under Control of Health Care Professionals, Organizations and/or Policymakers
</h3>
<div class='FieldValue'>
The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Time Window
</h3>
<div class='FieldValue'>
Episode of care
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Administrative data 
</div>
<div class='FieldValue'>
Laboratory data
</div>
<div class='FieldValue'>
Medical record
</div>
<div class='FieldValue'>
Pharmacy data
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Level of Determination of Quality
</h3>
<div class='FieldValue'>
Individual Case
</div>

</div>
<div class='field field_text'>
<h3>
Pre-existing Instrument Used
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Better quality is associated with a higher score
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Allowance for Patient Factors
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
Internal time comparison
</div>

</div>

</div>
<div class='section'>
<h2>Evaluation of Measure Properties
</h2>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Number of patients with antihypertensive therapy intensified / number of patients with advanced CKD, with blood pressure greater than 130/80 mmHg, and on antihypertensive medications.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Renal Physicians Association Clinical Performance Measures on Appropriate Patient Preparation for Renal Replacement Therapy
</div>

</div>
<div class='field field_text'>
<h3>
Measure Set Name
</h3>
<div class='FieldValue'>
Clinical Performance Measures for Hypertension Recommendations
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
Renal Physicians Association - Medical Specialty Society
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
Renal Physicians Association - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Ortho Biotech Products, LP</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>W. Kline Bolton, MD, Working Group Chair, University of Virginia School of Medicine, Charlottesville, VA; William F. Owen, Jr., MD, President, RPA, Duke University School of Medicine Durham, NC; Baxter Healthcare Corp., McGaw Park, IL; Dale Singer, MHA, Executive Director, RPA.</p>

<p><em>Content Experts</em>: Jack Coburn, MD, UCLA School of Medicine, West Los Angeles V.A. Healthcare Center, West Los Angeles, CA; William Haley, MD, Mayo Clinic, Jacksonville, FL; Annamaria Kausz, MD, New England Medical Center, Boston, MA; Adeera Levin, MD, St. Paul's Hospital, Vancouver, BC; William Mitch, MD, University of Texas Medical Branch, Galveston, TX; Patricia Painter, PhD, University of California, San Francisco, CA; Michael Rocco, MD, MSCE, Wake Forest University School of Medicine, Winston-Salem, NC.</p>

<p><em>Association Representatives</em>: Carolyn Atkins, RN, BS, CCTC, National Kidney Foundation, Medical City Dallas Hospital, Dallas, TX; Shelley Clark, RN, National Renal Administrators Association, FMC North Roanoke Dialysis, Roanoke, VA; Paul Eggers, PhD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD; Lori Fedje, RD, LD, NKF Council on Renal Nutrition, Pacific Northwest Renal Services, Portland, OR; Richard Goldman, MD, Renal Physicians Association, Renal Medicine Associates, Emeritus Albuquerque, NM; Joel Greer, PhD, Centers for Medicare and Medicaid Services, Baltimore, MD; Richard Lafayette, MD, American Society of Nephrology, Stanford University School of Medicine, Stanford, CA; Eugene Z. Oddone, MD, American College of Physicians - American Society of Internal Medicine, Durham VA Medical Center, Durham, NC; Victoria Norwood, MD, American Society of Pediatric Nephrology, University of Virginia, Charlottesville, VA; Paul M. Palevsky, MD, Forum of ESRD Networks, University of Pittsburgh School of Medicine, VA Pittsburgh Health Care System, Pittsburgh, PA; Sandy Peckens, MSW, NKF Council of Nephrology Social Workers, Merrimack Valley Nephrology, Methuen, MA; Venkateswara Rao, MD, American Society of Transplantation, Hennepin County Medical Center, Minneapolis, MN; Charlotte Thomas Hawkins, PhD, RN, CNN, American Nephrology Nurses Association, Rutgers, The State University of New Jersey, Burlington, NJ; Joseph White, American Association of Kidney Patients.</p>

<p><em>Methodologists</em>: David B. Matchar, MD, FACP, Director, Duke Center for Clinical Health Policy Research and Co-Director, Duke Evidence-based Practice Center, Durham, NC; Douglas C. McCrory, MD, MHS, Co-Director Duke Evidence-based Practice Center, Durham, NC; Joseph A. Coladonato, MD, Duke Institute of Renal Outcomes Research & Health Policy, Durham, NC; Preston S. Klassen, MD, MHS, Duke Institute of Renal Outcomes Research & Health Policy, Durham, NC; Meenal B. Patwardhan, MD, MHSA, Duke Center for Clinical Health Policy Research and Duke Evidence-based Practice Center, Durham, NC; Donal N. Reddan, MD, MHS, Duke Institute of Renal Outcomes Research & Health Policy, Durham, NC; Olivier T. Rutschmann, MD, MPH, Duke Center for Clinical Health Policy Research, Durham, NC; William S. Yancy, Jr., MD, MHS, Duke University Medical Center, Durham, NC.</p>

<p><em>Medical Editor</em>: Rebecca N. Gray, DPhil, Duke Evidence-based Practice Center, Durham, NC.</p>

<p><em>Project Manager and Editor</em>: Emily G. Shurr, MA, Duke Evidence-based Practice Center, Durham, NC.</p>
</div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>There were none disclosed.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Release Date
</h3>
<div class='FieldValue'>
2002 Oct
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Renal Physicians Association. Appropriate patient preparation for renal replacement therapy. Rockville (MD): Renal Physicians Association; 2002 Oct 1. 78 p.&nbsp;(Clinical Practice Guideline; no. 3).</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The individual measure, "Number of patients with antihypertensive therapy intensified / number of patients with advanced CKD, with blood pressure greater than 130/80 mmHg, and on antihypertensive medications," is published in "Renal Physicians Association Clinical Practice Guideline #3: Appropriate Patient Preparation for Renal Replacement Therapy."</p>

<p>For more information, contact RPA at 1700 Rockville Pike, Suite 220, Rockville, MD 20852; phone: 301-468-3515; fax: 301-468-3511; Web site: <a href="http://www.renalmd.org/" title="RPA Homepage" target="_blank">www.renalmd.org</a>; e-mail: <A href="mailto:rpa@renalmd.org">rpa@renalmd.org</A>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI on May 23, 2003.  The information was verified by the Renal Physicians Association on June 17, 2003.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p>

<p>For more information, contact RPA at 1700 Rockville Pike, Suite 220, Rockville, MD 20852; phone: 301-468-3515; fax: 301-468-3511; Web site: <a href="http://www.renalmd.org/" title="RPA Homepage" target="_blank">www.renalmd.org</a>; e-mail: <A href="mailto:rpa@renalmd.org">rpa@renalmd.org</A>.</p> </div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>